Tranexamic acid

Tranexamic acid (CAS 701-54-2) is a synthetic amino acid derivative used across pharmaceutical and cosmetic manufacturing as an antifibrinolytic and skin-brightening active. Known in the industry as TXA, it is a regulated pharmaceutical ingredient with a well-established global supply chain.

Procurement demand spans both finished dosage form production and bulk active ingredient sourcing. In pharmaceutical manufacturing, TXA is formulated into injectable solutions, tablets, and topical preparations indicated for bleeding control in surgical and trauma settings.

Cosmetic formulators incorporate it into serums, creams, and spot-treatment products targeting hyperpigmentation and uneven skin tone, where it functions as a melanin-inhibiting active. Oral solid dose manufacturers source it as an API for heavy menstrual bleeding treatments.

This represents a high-volume therapeutic segment with consistent global demand. Contract manufacturers producing combination topical formulations also use it alongside other brightening actives for premium skincare lines to enhance product efficacy.

Tranexamic acid is supplied as a white crystalline powder. It is available in pharmaceutical-grade specifications including USP, BP, and Ph. Eur., with API-grade material supported by DMF filings in major regulatory markets.

Cosmetic-grade material is also commercially available for personal care applications where pharmaceutical documentation is not required. The material is highly stable and compatible with a wide range of excipients and formulation bases.